Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
Regeneron Pharmaceuticals (NASDAQ: REGN) has announced a strategic collaboration with Truveta, Inc. and its U.S. health systems network, investing $119.5 million in Truveta's Series C financing round. The partnership launches the Truveta Genome Project, which aims to sequence up to ten million additional de-identified patient volunteers with linked electronic health records (EHRs).
The project will expand Regeneron Genetics Center's existing database of nearly three million exomes. RGC will conduct exome sequencing, genotyping, and imputation of the volunteers using biospecimens from Truveta's health system members. This data will integrate with Truveta's medical database, which represents over 120 million patients across 30 health systems.
Illumina, Inc. will also invest $20 million in the financing round. RGC will maintain exclusive rights to perform research-related sequencing on collected samples and access de-identified EHR data from study participants. The collaboration aims to accelerate drug target discovery, optimize clinical trials, and advance healthcare delivery.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha annunciato una collaborazione strategica con Truveta, Inc. e la sua rete di sistemi sanitari statunitensi, investendo 119,5 milioni di dollari nel round di finanziamento Series C di Truveta. La partnership lancia il Truveta Genome Project, che mira a sequenziare fino a dieci milioni di ulteriori volontari pazienti de-identificati collegati a cartelle cliniche elettroniche (EHR).
Il progetto espanderà il database esistente del Regeneron Genetics Center, che conta quasi tre milioni di esomi. RGC condurrà il sequenziamento degli esomi, la genotipizzazione e l'imputazione dei volontari utilizzando campioni biologici dei membri del sistema sanitario di Truveta. Questi dati si integreranno con il database medico di Truveta, che rappresenta oltre 120 milioni di pazienti in 30 sistemi sanitari.
Illumina, Inc. investirà anche 20 milioni di dollari nel round di finanziamento. RGC manterrà i diritti esclusivi per eseguire il sequenziamento legato alla ricerca sui campioni raccolti e accedere ai dati EHR de-identificati dei partecipanti allo studio. La collaborazione mira ad accelerare la scoperta di bersagli per farmaci, ottimizzare le sperimentazioni cliniche e migliorare la fornitura di assistenza sanitaria.
Regeneron Pharmaceuticals (NASDAQ: REGN) ha anunciado una colaboración estratégica con Truveta, Inc. y su red de sistemas de salud en EE. UU., invirtiendo 119,5 millones de dólares en la ronda de financiación Serie C de Truveta. La asociación lanza el Truveta Genome Project, que tiene como objetivo secuenciar hasta diez millones de voluntarios de pacientes desidentificados vinculados a registros electrónicos de salud (EHR).
El proyecto expandirá la base de datos existente del Regeneron Genetics Center, que cuenta con casi tres millones de exomas. RGC llevará a cabo el secuenciamiento de exomas, la genotipificación y la imputación de los voluntarios utilizando biospecímenes de los miembros del sistema de salud de Truveta. Estos datos se integrarán con la base de datos médica de Truveta, que representa a más de 120 millones de pacientes en 30 sistemas de salud.
Illumina, Inc. también invertirá 20 millones de dólares en la ronda de financiación. RGC mantendrá los derechos exclusivos para realizar secuenciación relacionada con la investigación sobre las muestras recolectadas y acceder a los datos de EHR desidentificados de los participantes en el estudio. La colaboración busca acelerar el descubrimiento de objetivos para fármacos, optimizar ensayos clínicos y avanzar en la atención sanitaria.
레제너론 제약 (NASDAQ: REGN)은 트루베타, Inc. 및 미국의 의료 시스템 네트워크와 전략적인 협력을 발표하며, 트루베타의 C 시리즈 자금 조달 라운드에 1억 1천 950만 달러를 투자했습니다. 이 파트너십은 트루베타 유전체 프로젝트를 시작하며, 이는 최대 1천만 명의 추가 비식별 환자 자원자를 전자 건강 기록 (EHR)과 연결하여 시퀀싱하는 것을 목표로 합니다.
이 프로젝트는 레제너론 유전학 센터의 기존 데이터베이스를 약 300만 개의 엑솜으로 확장할 것입니다. RGC는 트루베타의 의료 시스템 회원들로부터 생물 샘플을 사용하여 자원자들의 엑솜 시퀀싱, 유전자형 분석 및 대체 작업을 수행할 것입니다. 이 데이터는 30개 건강 시스템에 걸쳐 1억 2천만 명 이상의 환자를 나타내는 트루베타의 의료 데이터베이스와 통합될 것입니다.
일루미나, Inc.도 자금 조달 라운드에 2천만 달러를 투자할 예정입니다. RGC는 수집된 샘플에 대한 연구 관련 시퀀싱을 수행할 독점 권리를 유지하고 연구 참가자들의 비식별 EHR 데이터에 접근할 것입니다. 이 협력은 약물 표적 발견을 가속화하고, 임상 시험을 최적화하며, 의료 서비스 개선을 목표로 합니다.
Regeneron Pharmaceuticals (NASDAQ: REGN) a annoncé une collaboration stratégique avec Truveta, Inc. et son réseau de systèmes de santé aux États-Unis, en investissant 119,5 millions de dollars dans le tour de financement de Série C de Truveta. Ce partenariat lance le Truveta Genome Project, qui vise à séquencer jusqu'à dix millions de volontaires patients déidentifiés liés à des dossiers de santé électroniques (EHR).
Le projet va élargir la base de données existante du Regeneron Genetics Center, qui compte près de trois millions d'exomes. RGC effectuera le séquençage des exomes, la génotypage et l'imputation des volontaires en utilisant des biospécimens provenant des membres du système de santé de Truveta. Ces données s'intégreront dans la base de données médicale de Truveta, qui représente plus de 120 millions de patients à travers 30 systèmes de santé.
Illumina, Inc. investira également 20 millions de dollars dans le tour de financement. RGC maintiendra les droits exclusifs d'effectuer des séquençages liés à la recherche sur les échantillons collectés et d'accéder aux données EHR anonymisées des participants à l'étude. Cette collaboration vise à accélérer la découverte de cibles médicamenteuses, à optimiser les essais cliniques et à faire progresser la prestation des soins de santé.
Regeneron Pharmaceuticals (NASDAQ: REGN) hat eine strategische Zusammenarbeit mit Truveta, Inc. und deren Netzwerken in den US-Gesundheitssystemen angekündigt und investiert 119,5 Millionen USD in die Series-C-Finanzierungsrunde von Truveta. Die Partnerschaft startet das Truveta Genome Project, das zum Ziel hat, bis zu zehn Millionen weitere anonymisierte Patienten freiwillig mit verknüpften elektronischen Gesundheitsakten (EHRs) zu sequenzieren.
Das Projekt wird die bestehende Datenbank des Regeneron Genetics Center, die fast drei Millionen Exome umfasst, erweitern. RGC wird Exom-Sequenzierung, Genotypisierung und Imputation der Freiwilligen unter Verwendung von Bioproben der Mitglieder des Gesundheitssystems von Truveta durchführen. Diese Daten werden mit der medizinischen Datenbank von Truveta integriert, die über 120 Millionen Patienten aus 30 Gesundheitssystemen umfasst.
Illumina, Inc. wird ebenfalls 20 Millionen USD in die Finanzierungsrunde investieren. RGC wird die exklusiven Rechte behalten, forschungsbezogene Sequenzierung an den gesammelten Proben durchzuführen und auf anonymisierte EHR-Daten der Studien Teilnehmer zuzugreifen. Die Zusammenarbeit zielt darauf ab, die Entdeckung von Arzneimittelzielen zu beschleunigen, klinische Studien zu optimieren und die Gesundheitsversorgung voranzubringen.
- Strategic investment of $119.5 million secures exclusive research sequencing rights
- Massive expansion of genetic database from 3M to potentially 13M sequences
- Access to Truveta's extensive database of 120M+ patients across 30 health systems
- Additional $20M investment from Illumina strengthens project viability
- None.
Insights
This collaboration represents a strategic investment of
The deal's structure is particularly compelling: Regeneron secures exclusive rights to research-related sequencing while gaining access to Truveta's extensive healthcare records covering 120 million patients across 30 health systems. This combination of genomic and phenotypic data creates an unprecedented resource for target identification and drug development validation. Historical precedent suggests that larger genomic databases correlate strongly with increased drug target discovery success rates.
The technical implications of this collaboration are transformative. By combining Regeneron's existing 3 million exome database with up to 10 million new sequences, the enhanced statistical power will enable detection of rare genetic variants and complex trait associations that were previously undetectable. The inclusion of complete electronic health records adds important phenotypic context, allowing for more sophisticated genotype-phenotype correlations.
Illumina's
The value proposition extends beyond traditional drug discovery. This partnership creates a powerful platform for real-world evidence generation and precision medicine applications. The integration of genomic data with comprehensive electronic health records enables sophisticated patient stratification and could revolutionize clinical trial design and execution.
The collaboration's structure suggests potential future revenue streams through healthcare analytics and population health management solutions. For investors, this represents both near-term catalyst potential through accelerated drug discovery and long-term value creation through data monetization and healthcare optimization tools. This positions Regeneron at the forefront of the growing intersection between genomics, big data and personalized medicine.
The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project
Extensively expanded database effort is designed to dramatically accelerate discovery of new genetics-based drug targets and therapies, while also empowering the future of healthcare analytics and healthcare management
Regeneron investing
TARRYTOWN, N.Y., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic collaboration with Truveta, Inc. and its collective of U.S. health systems to advance innovation and data-driven discovery across the life sciences, public health and healthcare delivery ecosystem. Regeneron will provide a strategic investment of
"The scale and diversity of the Truveta Genome Project will enable us to explore the complex interplay between genetics and health in unprecedented detail,” said Aris Baras, M.D., Senior Vice President at Regeneron and Head of Regeneron Genetics Center (RGC). “With nearly three million exomes sequenced in our RGC database to date, Regeneron scientists have already identified dozens of genetic-based drug targets for a wide range of conditions – including chronic liver disease, obesity, cancer and neurodegenerative conditions – that have led to multiple clinical-stage medicines. As we continue to scale our genomics initiatives, we seek more targets and medicines, while expanding the potential impact of our research to optimize clinical trials and personalize healthcare delivery."
To enable the project, RGC will sequence the exomes and conduct genotyping and imputation of up to ten million de-identified consented volunteers using biospecimens provided by Truveta health system members across the nation. This genotypic data will be added to Truveta's unprecedented complete and timely de-identified medical database, representing more than 120 million patients across 30 health systems. The integration of these datasets is expected to yield actionable insights that have the potential to transform drug development, healthcare delivery and population health management.
“Nations have spent decades and billions of dollars to try and uncover the mysteries of biology to advance healthcare,” said Terry Myerson, Chief Executive Officer and co-founder of Truveta. “Just like volunteering to be an organ donor on your driver’s license is a simple act of service with a profound impact, the Truveta Genome Project enables each of us to anonymously contribute to dramatically accelerate progress in discovering the science of humanity, improving the health of our families and communities, and lowering the cost of care. Discoveries from smaller datasets have led to important new approaches to help prevent heart disease and restore hearing in children with certain forms of congenital deafness – it is so exciting to envision where a complete representative genomic dataset will guide us.”
Illumina, Inc., a long-standing RGC partner and a global leader in DNA sequencing and array-based technologies, will also invest
"Population scale omics initiatives like this hold incredible promise to accelerate new discoveries, improve human health, and advance healthcare equity for all communities. We are excited to bring our world-class sequencing technology to this important endeavor," said Jakob Wedel, Chief Strategy and Corporate Development Officer, Illumina.
RGC will have exclusive rights to perform all research-related sequencing on samples collected under the collaboration, in addition to access to the de-identified EHR data provided by each of the consented study participants. Additionally, Regeneron and Truveta plan to partner to utilize this data in the development of next-generation solutions for healthcare delivery and population health management.
“Big Data – combined with human ingenuity – is the key to driving next-generation scientific advancements. For nearly four decades, Regeneron has discovered and developed groundbreaking medicines that address the underlying causes of disease, and this next frontier of medicine will continue to be driven by innovative application of data,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. “By combining Regeneron’s expertise in genetics and drug development with Truveta's extensive phenotypic data and collaboration of leading U.S. health systems, we hope to create the ‘Big Data’ that will empower the next generation of drug discovery, as well as enable new approaches to healthcare analytics and healthcare management.”
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
About the Regeneron Genetics Center
Regeneron Genetics Center® (RGC™) is a genomic research initiative and a wholly owned subsidiary of Regeneron. For over a decade, we have harnessed the power of human genetics to discover important new medicines, validate existing research programs and optimize clinical trials. We tap into our growing database of more than 2.6 million sequenced exomes and de-identified health information using proprietary data analytics, technology and human ingenuity to make meaningful biological discoveries at speed and scale. Our high-touch integrated model focuses on working closely with our collaborators to build a dataset with meaningful cohorts. We use innovative technologies, such as machine learning, to sequence exomes, align with health information and perform large-scale analyses to make meaningful associations between genes and diseases. We apply our insights to guide Regeneron’s broader drug discovery and development efforts.
Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”), product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”), research and clinical programs now underway or planned, and the use of human genetics in Regeneron's research programs; the likelihood, timing, and scope of achieving any of the anticipated milestones discussed or referenced in this press release, including the launch of the Truveta Genome Project and any related research programs; the extent to which the results from research and development programs conducted by Regeneron and/or its collaborators or licensees (such as those that may result from Regeneron’s collaboration with Truveta, Inc. and the Truveta Genome Project discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; the availability and extent of reimbursement of Regeneron’s Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates (including biosimilar versions of Regeneron’s Products); unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), as well as the collaboration with Truveta, Inc. discussed in this press release, to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2023 and its Form 10-Q for the quarterly period ended September 30, 2024. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).
| Contacts: Media Relations Ella Campbell Tel: +1 914-572-4003 ella.campbell@regeneron.com | Investor Relations Mark Hudson Tel: +1 914-847-3483 mark.hudson@regeneron.com |
FAQ
What is the value of Regeneron's (REGN) investment in the Truveta Genome Project?
How many additional patient volunteers will be sequenced under the Truveta-REGN collaboration?
What exclusive rights does Regeneron (REGN) receive in the Truveta collaboration?
How many health systems and patients are represented in Truveta's database for REGN's research?
What is Illumina's investment role in the REGN-Truveta collaboration?
